FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks

Zevra Therapeutics Inc. (ZVRA) made headlines yesterday with a landmark FDA approval for its innovative drug, MIPLYFFA, in the treatment of Niemann-Pick disease type C. The regulatory development not only offers new hope for patients with this ultra-rare and progressive neurodegenerative disease but has also propelled Zevra shares to a new 52-week high.

from RTT - Top Story https://ift.tt/8A4rsu0
via IFTTT